{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:49:32Z","timestamp":1792082972199,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01669-2","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T06:48:24Z","timestamp":1771742904000},"page":"1739-1756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic Burden of Hidradenitis Suppurativa in Spain"],"prefix":"10.1007","volume":"16","author":[{"given":"Eva","family":"Vilarrasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lobo-Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Loro-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garcia N\u00fa\u00f1ez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Oliva-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Palacios-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Rubial-Bern\u00e1rdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoana","family":"Ivanova-Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7058-8659","authenticated-orcid":false,"given":"Mathilde","family":"Daheron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-1590","authenticated-orcid":false,"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"1669_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18. https:\/\/doi.org\/10.1038\/s41572-020-0149-1.","journal-title":"Nat Rev Dis Primers"},{"key":"1669_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.19556","volume":"183","author":"K Wolk","year":"2020","unstructured":"Wolk K, Join\u2010Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183:999\u20131010. https:\/\/doi.org\/10.1111\/bjd.19556.","journal-title":"Br J Dermatol"},{"key":"1669_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000453355","volume":"232","author":"A Kouris","year":"2017","unstructured":"Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et\u00a0al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2017;232:687\u201391. https:\/\/doi.org\/10.1159\/000453355.","journal-title":"Dermatology"},{"key":"1669_CR4","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.3390\/jcm13133900","volume":"13","author":"T Raudonis","year":"2024","unstructured":"Raudonis T, \u0160akaityt\u0117 A, Vileikis TP, \u010cernel V, Gancevi\u010dien\u0117 R, Zouboulis CC. Comorbidities, clinical presentation, subtypes, and treatment of HS patients in Lithuania. J Clin Med. 2024;13:3900. https:\/\/doi.org\/10.3390\/jcm13133900.","journal-title":"J Clin Med"},{"key":"1669_CR5","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de bimekizumab (Bimzelx\u00ae) en Hidradenitis Supurativa con una respuesta inadecuada al tratamiento sist\u00e9mico convencional [Internet]. 2024 [cited 2024 Dec 18]. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2024\/IPT-323-Bimzelx-bimekizumab.pdf. Accessed 18 Dec 2024."},{"key":"1669_CR6","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de secukinumab (Cosentyx\u00ae) en Hidradenitis Supurativa con una respuesta inadecuada al tratamiento sist\u00e9mico convencional [Internet]. 2024 [cited 2024 June 11]. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2024\/IPT-280-Cosentyx-secukinumab.pdf. Accessed 11 June 2024."},{"key":"1669_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/ijd.13703","volume":"56","author":"JV Santos","year":"2017","unstructured":"Santos JV, Lisboa C, Lanna C, Costa-Pereira A, Freitas A. Is the prevalence of hidradenitis suppurativa being overestimated in Europe? Or is the disease underdiagnosed? Evidence from a nationwide study across Portuguese public hospitals. Int J Dermatol. 2017;56:1491\u20132. https:\/\/doi.org\/10.1111\/ijd.13703.","journal-title":"Int J Dermatol"},{"key":"1669_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et\u00a0al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236:421\u201330. https:\/\/doi.org\/10.1159\/000508787.","journal-title":"Dermatology"},{"key":"1669_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.237","author":"E Vilarrasa","year":"2023","unstructured":"Vilarrasa E, Molina-Leyva A, Mart\u00edn V, Coak E, Truman I, Wallinger H, et\u00a0al. Unmet clinical needs, burden of disease and treatment patterns in hidradenitis suppurativa: real-world experience from Spain. JEADV Clin Pract. 2023. https:\/\/doi.org\/10.1002\/jvc2.237.","journal-title":"JEADV Clin Pract."},{"key":"1669_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ad.2015.06.005","volume":"106","author":"A Martorell","year":"2015","unstructured":"Martorell A, Garc\u00eda FJ, Jim\u00e9nez-Gallo D, Pascual JC, Pereyra-Rodr\u00edguez J, Salgado L, et\u00a0al. Actualizaci\u00f3n en hidradenitis supurativa (ii): aspectos terap\u00e9uticos. Actas Dermosifiliogr. 2015;106:716\u201324. https:\/\/doi.org\/10.1016\/j.ad.2015.06.005.","journal-title":"Actas Dermosifiliogr"},{"key":"1669_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1403455","author":"P Mendes-Bastos","year":"2024","unstructured":"Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I, et\u00a0al. Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1403455.","journal-title":"Front Med"},{"key":"1669_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/bjd.14976","volume":"176","author":"N Desai","year":"2017","unstructured":"Desai N, Shah P. High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics. Br J Dermatol. 2017;176:1048\u201355. https:\/\/doi.org\/10.1111\/bjd.14976.","journal-title":"Br J Dermatol"},{"key":"1669_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255560","volume":"16","author":"VG Frings","year":"2021","unstructured":"Frings VG, Sch\u00f6ffski O, Goebeler M, Presser D. Economic analysis of the costs associated with hidradenitis suppurativa at a German University Hospital. PLoS ONE. 2021;16:e0255560. https:\/\/doi.org\/10.1371\/journal.pone.0255560.","journal-title":"PLoS ONE"},{"key":"1669_CR14","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.1016\/j.jval.2023.03.2066","volume":"26","author":"J Voorham","year":"2023","unstructured":"Voorham J, Tran T, Ploug U, Keal A, Beaty S, Shang A. RWD36 healthcare resource utilization in patients with hidradenitis suppurativa in five European countries and the USA using real world evidence. Value Health. 2023;26:S367. https:\/\/doi.org\/10.1016\/j.jval.2023.03.2066.","journal-title":"Value Health."},{"key":"1669_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14737167.2021.1895753","volume":"22","author":"K G\u00e1sp\u00e1r","year":"2022","unstructured":"G\u00e1sp\u00e1r K, Hunor Gergely L, Jenei B, Wikonk\u00e1l N, Kiny\u00f3 \u00c1, Szegedi A, et\u00a0al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res. 2022;22:399\u2013408. https:\/\/doi.org\/10.1080\/14737167.2021.1895753.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1669_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/bjd\/ljac027","volume":"188","author":"S Schneider-Burrus","year":"2023","unstructured":"Schneider-Burrus S, Kalus S, Fritz B, Wolk K, Gomis-Kleindienst S, Sabat R. The impact of hidradenitis suppurativa on professional life. Br J Dermatol. 2023;188:122\u201330. https:\/\/doi.org\/10.1093\/bjd\/ljac027.","journal-title":"Br J Dermatol"},{"key":"1669_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327\u201337. https:\/\/doi.org\/10.3350\/cmh.2014.20.4.327.","journal-title":"Clin Mol Hepatol"},{"key":"1669_CR18","unstructured":"Instituto Nacional de Estad\u00edstica. \u00cdndice de Precios de Consumo. Base 2021. Medias anuales. \u00cdndices nacionales: general y de grupos ECOICOP [Internet]. 2024 [cited 2025 Jan 15]. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=50934. Accessed 15 Jan 2025."},{"key":"1669_CR19","unstructured":"Instituto Nacional de Estad\u00edstica. Proyecci\u00f3n de la poblaci\u00f3n de Espa\u00f1a. Resultados nacionales: serie 2022\u20132072. Poblaci\u00f3n residente en Espa\u00f1a a 1 de enero, por sexo, edad y a\u00f1o [Internet]. 2024 [cited 2024 Mar 19]. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=36643. Accessed 19 Mar 2024."},{"key":"1669_CR20","unstructured":"Survey of patients with hidradenitis suppurativa as part of the \u2018AvanceHS\u2019 project. 2025."},{"key":"1669_CR21","unstructured":"Median of the Official Bulletins of the Autonomous Communities. 2024."},{"key":"1669_CR22","unstructured":"Ministerio de Sanidad. Subdirecci\u00f3n General de Informaci\u00f3n Sanitaria. Registro de Actividad de Atenci\u00f3n Especializada\u2014RAE-CMBD. Diagn\u00f3sticos principales. L73.2-Hidradenitis supurativa [Internet]. 2023 [cited 2024 Jan 11]. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/PUBLICOSNS. Accessed 11 Jan 2024."},{"key":"1669_CR23","unstructured":"UCB Advisory Board. 2024."},{"key":"1669_CR24","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Centro de informaci\u00f3n de medicamentos [Internet]. https:\/\/www.google.com\/search?q=cima&oq=cima&aqs=chrome.0.69i59j35i39j0i131i433i512j0i433i512j0i512l2j69i60l2.592j0j7&sourceid=chrome&ie=UTF-8."},{"key":"1669_CR25","unstructured":"Consejo General de Colegios Farmac\u00e9uticos. BOTPLUS drugs database [Internet]. [cited 2025 Apr 4]. https:\/\/botplusweb.farmaceuticos.com\/. Accessed 4 Apr 2025."},{"key":"1669_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jdv.12567","volume":"29","author":"E Shavit","year":"2015","unstructured":"Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:371\u20136. https:\/\/doi.org\/10.1111\/jdv.12567.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1669_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s10597-012-9503-4","volume":"48","author":"J Rovira","year":"2012","unstructured":"Rovira J, Albarracin G, Salvador L, Rejas J, S\u00e1nchez-Iriso E, Cabas\u00e9s JM. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study. Community Ment Health J. 2012;48:372\u201383. https:\/\/doi.org\/10.1007\/s10597-012-9503-4.","journal-title":"Community Ment Health J"},{"key":"1669_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euroneuro.2021.04.022","volume":"50","author":"E Vieta","year":"2021","unstructured":"Vieta E, Alonso J, P\u00e9rez-Sola V, Roca M, Hernando T, Sicras-Mainar A, et\u00a0al. Epidemiology and costs of depressive disorder in Spain: the EPICO study. Eur Neuropsychopharmacol. 2021;50:93\u2013103. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.04.022.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1669_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10198-003-0189-y","volume":"5","author":"B van den Berg","year":"2004","unstructured":"van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care. Eur J Health Econ. 2004;5:36\u201345. https:\/\/doi.org\/10.1007\/s10198-003-0189-y.","journal-title":"Eur J Health Econ"},{"key":"1669_CR30","unstructured":"Instituto de Mayores y Servicios Sociales. Servicios sociales dirigidos a las personas mayores [Internet]. 2023. https:\/\/imserso.es\/documents\/20123\/8735791\/inf_ssppmmesp2023.pdf\/634ffac5-32f2-f7b3-3c4a-fc43179676de."},{"key":"1669_CR31","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1136\/ard.2009.117150","volume":"69","author":"WB van den Hout","year":"2010","unstructured":"van den Hout WB, BMJ Publishing Group Ltd. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69:i89-91. https:\/\/doi.org\/10.1136\/ard.2009.117150.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR32","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta anual de estructura salarial. Resultados nacionales. Ganancia media anual por trabajador. Sexo y edad. [Internet]. 2022 [cited 2025 May 3]. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=28189. Accessed 3 May 2025."},{"key":"1669_CR33","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta de poblaci\u00f3n activa. N\u00famero medio de horas efectivas semanales trabajadas por todos los ocupados (hayan o no trabajado en la semana) por situaci\u00f3n profesional, sexo y rama de actividad (empleo principal). [Internet]. 2024 [cited 2025 Mar 18]. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=65983. Accessed 18 Mar 2025."},{"key":"1669_CR34","unstructured":"Instituto Nacional de Estad\u00edstica. Poblaci\u00f3n en viviendas familiares. Poblaci\u00f3n por nacionalidad, sexo y grupo de edad [Internet]. 2021 [cited 2025 Apr 28]. https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=65065. Accessed 28 Apr 2025."},{"key":"1669_CR35","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta de poblaci\u00f3n activa. Ocupados por sexo y grupo de edad. Valores absolutos y porcentajes respecto del total de cada sexo [Internet]. 2024 [cited 2025 Apr 15]. https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=65962&L=0. Accessed 15 Apr 2025."},{"key":"1669_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)75247-5","volume":"12","author":"J S\u00e1nchez-Carazo","year":"2009","unstructured":"S\u00e1nchez-Carazo J, Daud\u00e9n E, Vanaclocha F, Toribio J, Pujol R, Puig L, et\u00a0al. PSS10 cost of moderate to severe psoriasis patients in Spain. Value Health. 2009;12:A454. https:\/\/doi.org\/10.1016\/S1098-3015(10)75247-5.","journal-title":"Value Health"},{"key":"1669_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ad.2022.08.015","volume":"114","author":"E Artime","year":"2023","unstructured":"Artime E, Serra E, Mert C, D\u00edaz-Cerezo S, Huete T, Hern\u00e1ndez-Subir\u00e1 I, et\u00a0al. Real-world treatment patterns, resource use and costs in adult patients with atopic dermatitis receiving systemic treatment: derma-atopic study in Spain. Actas Dermo-Sifiliogr. 2023;114:9\u201318. https:\/\/doi.org\/10.1016\/j.ad.2022.08.015.","journal-title":"Actas Dermo-Sifiliogr"},{"key":"1669_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10198-016-0799-9","volume":"18","author":"J Alvarez-Sab\u00edn","year":"2017","unstructured":"Alvarez-Sab\u00edn J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, et\u00a0al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017;18:449\u201358. https:\/\/doi.org\/10.1007\/s10198-016-0799-9.","journal-title":"Eur J Health Econ"},{"key":"1669_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s41669-023-00451-w","volume":"8","author":"L G\u00f3mez Maldonado","year":"2023","unstructured":"G\u00f3mez Maldonado L, de Mora-Figueroa R, L\u00f3pez-Angarita A, Maravilla-Herrera P, Merino M. Cost of patients with Alzheimer\u2019s disease in Spain according to disease severity. PharmacoEconomics Open. 2023;8:103\u201314. https:\/\/doi.org\/10.1007\/s41669-023-00451-w.","journal-title":"PharmacoEconomics Open"},{"key":"1669_CR40","unstructured":"UCB. BIMZELX\u00ae (bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) [Internet]. 2025 [cited 2025 May 13]. https:\/\/www.ucb.com\/sites\/default\/files\/press_files\/89bdb5d3c4205714.pdf. Accessed 13 May 2025."},{"key":"1669_CR41","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s13555-023-00954-8","volume":"13","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Rahawi K, Duan Y, Lane M, Amin AZ, Sayed CJ. Effect of biologics on the need for procedural interventions, systemic medications, and healthcare utilization in patients with hidradenitis suppurativa: real-world data from the UNITE registry. Dermatol Ther Heidelb. 2023;13:1577\u201385. https:\/\/doi.org\/10.1007\/s13555-023-00954-8.","journal-title":"Dermatol Ther Heidelb"},{"key":"1669_CR42","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1111\/jdv.13307","volume":"29","author":"B Polistena","year":"2015","unstructured":"Polistena B, Calzavara-Pinton P, Altomare G, Berardesca E, Girolomoni G, Martini P, et\u00a0al. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. J Eur Acad Dermatol Venereol. 2015;29:2411\u20136. https:\/\/doi.org\/10.1111\/jdv.13307.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1669_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, et\u00a0al. Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real\u2010life multicentre cohort study*. Br J Dermatol. 2021;184:133\u201340. https:\/\/doi.org\/10.1111\/bjd.18983.","journal-title":"Br J Dermatol"},{"key":"1669_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.12.005","author":"FJ Melgosa Ramos","year":"2024","unstructured":"Melgosa Ramos FJ, Garc\u00eda-Ruiz R, Mateu Puchades A, Martorell A. Podemos mejorar el pron\u00f3stico de la hidradenitis supurativa? Definiendo a los pacientes en la \u00abventana de oportunidad\u00bb. Actas Dermosifiliogr. 2024. https:\/\/doi.org\/10.1016\/j.ad.2022.12.005.","journal-title":"Actas Dermosifiliogr"},{"key":"1669_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","volume":"21","author":"ZS Patel","year":"2017","unstructured":"Patel ZS, Hoffman LK, Buse DC, Grinberg AS, Afifi L, Cohen SR, et\u00a0al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21:49. https:\/\/doi.org\/10.1007\/s11916-017-0647-3.","journal-title":"Curr Pain Headache Rep"},{"key":"1669_CR46","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.43124","volume":"105","author":"F Regensberger","year":"2025","unstructured":"Regensberger F, Andr\u00e9 F, Schmuth M. Flare-ups: new insights into the burden of pain in hidradenitis suppurativa. Acta Derm Venereol. 2025;105:43124. https:\/\/doi.org\/10.2340\/actadv.v105.43124.","journal-title":"Acta Derm Venereol"},{"key":"1669_CR47","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/1346-8138.16868","volume":"50","author":"P Towfighi","year":"2023","unstructured":"Towfighi P, Huffman SS, Bovill JD, Shan HD, Haffner ZK, Kim EY, et\u00a0al. Financial toxicity of hidradenitis suppurativa: a single-center experience at an urban wound-care clinic. J Dermatol. 2023;50:1279\u201386. https:\/\/doi.org\/10.1111\/1346-8138.16868.","journal-title":"J Dermatol"},{"key":"1669_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","volume":"10","author":"T Tzellos","year":"2020","unstructured":"Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb). 2020;10:63\u201371. https:\/\/doi.org\/10.1007\/s13555-020-00354-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1669_CR49","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jaad.2017.07.027","volume":"77","author":"IH Hamzavi","year":"2017","unstructured":"Hamzavi IH, Sundaram M, Nicholson C, Zivkovic M, Parks-Miller A, Lee J, et\u00a0al. Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol. 2017;77:1038\u201346. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.027.","journal-title":"J Am Acad Dermatol"},{"key":"1669_CR50","unstructured":"Bowling. Research methods in health: investigating health and health services. McGraw-Hill Education (UK); 2014."},{"key":"1669_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181:147\u201354. https:\/\/doi.org\/10.1111\/bjd.17101.","journal-title":"Br J Dermatol"},{"key":"1669_CR52","unstructured":"Asociaci\u00f3n de enfermos de hidrosadenitis. Encuesta sobre la situaci\u00f3n de los pacientes con Hidradenitis Supurativa en Espa\u00f1a. III Bar\u00f3metro Hidradenitis Supurativa [Internet]. 2022. https:\/\/asendhi.org\/wp-content\/uploads\/2020\/05\/III-Barometro-Hidradenitis-Supurativa-ASENDHI-comprimido.pdf. Accessed 21 June 2023."},{"key":"1669_CR53","unstructured":"Ministerio de Sanidad. Registro de Actividad de Atenci\u00f3n Especializada - RAE-CMBD. Diagn\u00f3sticos principales. Catalu\u00f1a. [Internet]. 2022 [cited 2024 Oct 9]. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/S. Accessed 9 Oct 2024."},{"key":"1669_CR54","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. CIMA. Centro de informaci\u00f3n de medicamentos [Internet]. [cited 2020 Mar 1]. https:\/\/cima.aemps.es\/cima\/publico\/home.html. Accessed 1 Mar 2020."},{"key":"1669_CR55","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Aportaci\u00f3n al pago de medicamentos por receta en el SNS [Internet]. https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/sisInfSanSNS\/pdf\/aportacionRecetaSNS.pdf."},{"key":"1669_CR56","unstructured":"Jefatura del Estado. BOE n\u00fam 126, de 24 de mayo de 2010. Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. 2010."},{"key":"1669_CR57","unstructured":"Ministerio de Sanidad. BIFIMED: Buscador de la informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos [Internet]. 2024 [cited 2024 Mar 19]. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do. Accessed 19 Mar 2024."},{"key":"1669_CR58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et\u00a0al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) project. J Am Acad Dermatol. 2020;82:366\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1301.","journal-title":"J Am Acad Dermatol"},{"key":"1669_CR59","unstructured":"UCB data on file. UCB data on file (2023a). Phase 3 (BE HEARD I & II) Post-hoc analyses, CSRs, and EQ-5D data. 2023."},{"key":"1669_CR60","unstructured":"Asumption."},{"key":"1669_CR61","unstructured":"Roman\u00ed de Gabriel J, Ciudad Blanco MC, Martorell Calatayud AJ, Pascual Ram\u00edrez JC, Gonz\u00e1lez L\u00f3pez MA, Molina Leyva A, et\u00a0al. Recomendaciones en la atenci\u00f3n de pacientes con hidradenitis supurativa en consultas de dermatolog\u00eda especializada [Internet]. 2020. https:\/\/www.antares-consulting.com\/recomendaciones-en-la-atencion-de-pacientes-con-hidradenitis-supurativa-en-consultas-de-dermatologia-especializada\/."},{"key":"1669_CR62","unstructured":"Junta de Andaluc\u00eda, Hospital Universitario Virgen del Roc\u00edo. Ecograf\u00eda [Internet]. Hospital Universitario Virgen del Roc\u00edo. 2024 [cited 2024 Apr 23]. https:\/\/hospitaluvrocio.es\/entrada-blog\/ecografia\/. Accessed 23 Apr 2024."},{"key":"1669_CR63","unstructured":"Osakidetza. Resonancia magn\u00e9tica [Internet]. 2020 [cited 2024 Apr 23]. https:\/\/www.osakidetza.euskadi.eus\/resonancia-magnetica\/webosk00-otkcon\/es\/. Accessed 23 Apr 2024."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01669-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:53Z","timestamp":1774372013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01669-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01669-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoana Ivanova Markova and Mathilde Daheron are employed by Weber Espa\u00f1a, a company that received funding from UCB to conduct this study. Javier Bellas is an employee of UCB. Eva Vilarrasa, Joaqu\u00edn Borr\u00e1s Blasco, Silvia Lobo Benito, Marta Loro P\u00e9rez, Marta Garc\u00eda N\u00fa\u00f1ez-Garc\u00eda, Juan Oliva Moreno, David Palacios Mart\u00ednez, F\u00e9lix Rubial Bern\u00e1rdez, and Antonio Martorell received fees from UCB for their expert advice during study conduction. Eva Vilarrasa has received funding and\/or honoraria for educational activities, consultancy, advisory roles, or speaking engagements from Abbvie, Aceleryn, Almirall, Amgen, Bayer, Biofrontera, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Galderma, Gebro, Incyte, Isdin, Johnson and Johnson, Leo Pharma, Lilly, Merck-Serono, MoonLake, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. She has also worked as a consultant, investigator, or collaborator with the following companies and startups: iDermApp, Mediktor, DermUS, Biomi, and Barcelona Health Hub. Eva Vilarrasa is an Editorial Board member of Dermatology and Therapy. Eva Vilarrasa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Joaqu\u00edn Borr\u00e1s Blasco has received funding and\/or honoraria for educational activities, consultancy, research, or speaking engagements at events of medical and scientific interest from Boehringer Ingelheim, Johnson and Johnson, Pfizer, Sanofi, and UCB. Antonio Martorell has received honoraria and\/or travel grants and\/or has served as a member of advisory committees for Abbvie, Aceleryn, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Incyte, Johnson and Johnson, Leo Pharma, MoonLake, Novartis, Pfizer, Sandoz, Sanofi, UCB, and Legit Health. He has also served as a principal investigator in clinical trials sponsored by Abbvie, Aceleryn, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Incyte, Johnson and Johnson, Leo Pharma, MoonLake, Novartis, Pfizer, MSD, Takeda, Sanofi, UCB, and MSD. Marta Loro P\u00e9rez has received financial support for collaborative research projects or and\/or consultancy honoraria from Janssen-Cilag, Pzfizer, Novartis, Abbvie and UCB. Juan Oliva Moreno, Silvia Lobo Benito, Marta Garc\u00eda N\u00fa\u00f1ez-Garc\u00eda, David Palacios Mart\u00ednez and F\u00e9lix Rubial Bern\u00e1rdez do not declare any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"No ethical approval was required for this study, as the data were obtained from previously approved studies\/registries. Data sourced from the AvanceHS survey were analyzed in anonymized form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}